Global Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Drug Type (Phosphodiestrase-4 Inhibitors, Long-Acting Bronchodilators, Short-Acting Bronchodilators, Methylxanthines, Corticosteroids), Product Type (Inhalers, Nebulizers), Type (Chronic Bronchitis, Emphysema), Diagnosis (Pirometry, Diagnostic Tests, Others), Treatment (Oxygen Therapy, Lung Transplant, Drug Therapy, Vaccination, Surgery, Others), End User (Hospitals & Clinics, Home Care Settings, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Chronic Obstructive Pulmonary Disease (COPD) Drug Market
The chronic obstructive pulmonary disease (COPD) drug market is expected to witness market growth at a rate of 5.05% in the forecast period of 2021 to 2028. Data Bridge Market Research report on chronic obstructive pulmonary disease (COPD) drug market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The increase in the prevalence of respiratory diseases globally is escalating the growth of chronic obstructive pulmonary disease (COPD) drug market.
Chronic obstructive pulmonary disease (COPD) refers to a common, preventable, incurable, and treatable disease which displays persistent respiratory symptoms and airflow limitation. Chronic inflammation in the airways leading to alveolar abnormalities could be caused by long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution.
The rise in the prevalence of chronic obstructive pulmonary disease (COPD) among population across the globe, acts as one of the major factors driving the growth of chronic obstructive pulmonary disease (COPD) drug market. The increase in demand for home care therapeutic and treatments for the chronic respiratory disease due to the comfort and ease and rise in demand for the drugs to treat breathing difficulty, cough, mucus production and wheezing accelerate the chronic obstructive pulmonary disease (COPD) drug market growth. The growth in awareness regarding respiratory diseases and treatments and precautions associated with the diseases further influence the chronic obstructive pulmonary disease (COPD) drug market. Additionally, rise in pollution, industrialization, research and development and surge in healthcare expenditure positively affect the chronic obstructive pulmonary disease (COPD) drug market. Furthermore, technological advancements and new product launches extend profitable opportunities to the chronic obstructive pulmonary disease (COPD) drug market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatment and patent expiry is the factors expected to obstruct the chronic obstructive pulmonary disease (COPD) drug market growth. The presence of stringent government regulations is projected to challenge the chronic obstructive pulmonary disease (COPD) drug market in the forecast period of 2021-2028.
This chronic obstructive pulmonary disease (COPD) drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on chronic obstructive pulmonary disease (COPD) drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Chronic Obstructive Pulmonary Disease (COPD) Drug Market Scope and Market Size
The chronic obstructive pulmonary disease (COPD) drug market is segmented on the basis of drug type, product type, type, diagnosis, treatment and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug type, the chronic obstructive pulmonary disease (COPD) drug market is segmented into phosphodiestrase-4 inhibitors, long-acting bronchodilators, short-acting bronchodilators, methylxanthines and corticosteroids.
- On the basis of product type, the chronic obstructive pulmonary disease (COPD) drug market is segmented into inhalers and nebulizers. Inhalers are further segmented into dry powder inhalersm, metered dose inhalers and soft mist inhalers. Nebulizers are further segmented into ultrasonic nebulizers and jet nebulizers.
- On the basis of type, the chronic obstructive pulmonary disease (COPD) drug market is segmented into chronic bronchitis and emphysema.
- On the basis of diagnosis, the chronic obstructive pulmonary disease (COPD) drug market is segmented into pirometry, diagnostic tests and others.
- On the basis of treatment, the chronic obstructive pulmonary disease (COPD) drug market is segmented into oxygen therapy, lung transplant, drug therapy, vaccination, surgery and others. Drug Therapy is further segmented into inhaled steroids, combination inhalers, oral steroids and others.
- On the basis of end user, the chronic obstructive pulmonary disease (COPD) drug market is segmented into hospitals and clinics, home care settings and others.
Global Chronic Obstructive Pulmonary Disease (COPD) Drug Market Country Level Analysis
The chronic obstructive pulmonary disease (COPD) drug market is analyzed and market size information is provided by country, drug type, product type, type, diagnosis, treatment and end user as referenced above.
The countries covered in the global chronic obstructive pulmonary disease (COPD) drug market report are the U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the chronic obstructive pulmonary disease (COPD) drug market due to the increasing patient population suffering from COPD and the presence of major market players within the region. Asia-Pacific is expected to witness the fastest growth during the forecast period of 2021 to 2028 because of the high patient population suffering from COPD and the rising prevalence of respiratory disease.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The chronic obstructive pulmonary disease (COPD) drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to chronic obstructive pulmonary disease (COPD) drug market growth is analyzed to create a more robust and cohort multivariate statistical model for forecasting the chronic obstructive pulmonary disease (COPD) drug market in the growth period.
Competitive Landscape and Chronic Obstructive Pulmonary Disease (COPD) Drug Market Share Analysis
The chronic obstructive pulmonary disease (COPD) drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to chronic obstructive pulmonary disease (COPD) drug market.
The major players covered in the chronic obstructive pulmonary disease (COPD) drug market report are AstraZeneca, GlaxoSmithKline plc, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Aché Laboratórios Farmacêuticos S.A., bioMARCK, Aquinox Pharmaceuticals, Astellas Pharma Inc., Abbott., F. Hoffmann-La Roche Ltd, Adamis Pharmaceuticals Corporation, Sunovion Pharmaceuticals Inc., Mylan N.V., Orion Corporation, Grifols, S.A., Theravance Biopharma, Circassia, ResMed among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
